New cancer pill enters human testing for Tough-to-Treat tumors
NCT ID NCT04045496
Summary
This first-in-human study tested a new oral drug called JAB-3312 in 40 adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find the safest dose and see how the body processes the drug. Researchers also looked for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HealthONE Clinic Services Oncology-Hematology
Denver, Colorado, 80202, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Washington University School of Medicine
Seattle, Washington, 63110, United States
Conditions
Explore the condition pages connected to this study.